163 related articles for article (PubMed ID: 32451762)
1. Annexin A10 is a novel prognostic biomarker of papillary thyroid cancer.
Liu X; Yang M; Guo Y; Lu X
Ir J Med Sci; 2021 Feb; 190(1):59-65. PubMed ID: 32451762
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of ANXA10 inhibits proliferation and promotes apoptosis of papillary thyroid carcinoma cells by down-regulating TSG101 thereby inactivating the MAPK/ERK signaling pathway.
Wei T; Zhu X
J Bioenerg Biomembr; 2021 Aug; 53(4):429-440. PubMed ID: 34032966
[TBL] [Abstract][Full Text] [Related]
3. Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma.
Ishikawa A; Kuraoka K; Zaitsu J; Saito A; Kuwai T; Shimizu Y; Sudo T; Tashiro H; Taniyama K; Yasui W
Anticancer Res; 2021 Mar; 41(3):1349-1355. PubMed ID: 33788726
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Increased Expression of Annexin A10 (ANXA10) in Serous Epithelial Ovarian Cancer.
Wang J; Zhao S; Wang F; Wang J; Zhang Y
Med Sci Monit; 2019 Jul; 25():5666-5673. PubMed ID: 31363077
[TBL] [Abstract][Full Text] [Related]
5. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Sun R; Liu Z; Qiu B; Chen T; Li Z; Zhang X; Xu Y; Zhang Z
EBioMedicine; 2019 Sep; 47():142-155. PubMed ID: 31492557
[TBL] [Abstract][Full Text] [Related]
6. High Annexin A10 expression is correlated with poor prognosis in pancreatic ductal adenocarcinoma.
Ishikawa A; Kuraoka K; Zaitsu J; Saito A; Yamaguchi A; Kuwai T; Sudo T; Hadano N; Tashiro H; Taniyama K; Yasuif W
Histol Histopathol; 2022 Mar; 37(3):243-250. PubMed ID: 34821375
[TBL] [Abstract][Full Text] [Related]
7. Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma.
Yumura M; Nagano T; Jimbo N; Dokuni R; Kiriu T; Tanaka Y; Tachihara M; Itoh T; Maniwa Y; Nishimura Y; Kobayashi K
Anticancer Res; 2022 Mar; 42(3):1289-1294. PubMed ID: 35220218
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
9. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.
Che X; Zhang G; Zhang X; Xue J
Med Sci Monit; 2018 May; 24():3540-3548. PubMed ID: 29805156
[TBL] [Abstract][Full Text] [Related]
11. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
12. Loss of Annexin A10 Expression Is Associated with Poor Prognosis in Early Gastric Cancer.
Ishikawa A; Kuraoka K; Zaitsu J; Saito A; Kuwai T; Suzuki T; Tashiro H; Taniyama K; Yasui W
Acta Histochem Cytochem; 2020 Oct; 53(5):113-119. PubMed ID: 33177783
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Forkhead box Q1 correlates with poor prognosis in papillary thyroid carcinoma.
Li Y; Wang HQ; Wang AC; Li YX; Ding SS; An XJ; Shi HY
Clin Endocrinol (Oxf); 2019 Feb; 90(2):334-342. PubMed ID: 30378716
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of annexin A family in glioblastoma.
Xu H; Wu X; Dou Y; Zheng W
Ir J Med Sci; 2022 Aug; 191(4):1539-1547. PubMed ID: 34398393
[TBL] [Abstract][Full Text] [Related]
15. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.
Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH
Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394
[TBL] [Abstract][Full Text] [Related]
16. Annexin A10 in human oral cancer: biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways.
Shimizu T; Kasamatsu A; Yamamoto A; Koike K; Ishige S; Takatori H; Sakamoto Y; Ogawara K; Shiiba M; Tanzawa H; Uzawa K
PLoS One; 2012; 7(9):e45510. PubMed ID: 23029062
[TBL] [Abstract][Full Text] [Related]
17. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
[TBL] [Abstract][Full Text] [Related]
18. Correlations of ultrasound and pathological features of thyroid carcinoma with TC-1 mRNA and protein expression.
Zhang CL; Geng CH; Jian JJ; He M; Zhao HW; Li HY
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3440-3446. PubMed ID: 31081098
[TBL] [Abstract][Full Text] [Related]
19. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.
Kim JH; Rhee YY; Kim KJ; Cho NY; Lee HS; Kang GH
APMIS; 2014 Dec; 122(12):1187-95. PubMed ID: 24909058
[TBL] [Abstract][Full Text] [Related]
20. Annexin A10 is involved in the induction of pancreatic duodenal homeobox‑1 in gastric cancer tissue, cells and organoids.
Ishikawa A; Sakamoto N; Honma R; Taniyama D; Fukada K; Hattori T; Sentani K; Oue N; Yanagihara K; Tanabe K; Ohdan H; Yasui W
Oncol Rep; 2020 Feb; 43(2):581-590. PubMed ID: 31789399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
